Skip to content

Author

Haixiang Qi

We have 2 of 6 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Oct 2026

Discovery of 4-Aminoquinazoline Derivatives as Potent PKMYT1 Inhibitors via Hydrogen Bond Donor-To-Acceptor Conversion for CCNE1 -Amplified Cancers

PKMYT1 is a critical regulator of the cell cycle and has emerged as a promising synthetic lethal target for CCNE1-amplified cancers. In this study, we report the design, synthesis, and biological evaluation of a novel series of 4-aminoquinazoline-based PKMYT1 inhibitors. A hydrogen bond donor-to-acceptor conversion s...

Hai-Xiang Qi, Rui Lu, Yi-Fei Zhu et al. · 0 citations
Review Jul 2026

A patent review of mutant-selective PI3Kα inhibitors for the treatment of different cancers (2021–2025)

This review evaluates patents of PI3Kα mutant-selective inhibitors disclosed between 2021 and 2025 and examines the binding modes across two distinct allosteric domains: an H1047R-specific pocket (exemplified by Eli Lilly's inhibitors) and a pan-mutant cryptic site (engaged by RLY-2608 and STX-478).

Haixiang Qi, Jia-Yang Wen, Heng Xu · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.